---
title: "TransCode Therapeutics (RNAZ) news: reverse split and delisting"
url: "https://aibio.space/companies/transcode-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RNAZ reverse split, delisting, going concern, offering, Nasdaq notice and merger news: TransCode Therapeutics faces Nasdaq delisting with no grace period…"
---

RNAZ TransCode Therapeutics, Inc. NASDAQ · United States

# TransCode Therapeutics (RNAZ) news RNAZ reverse split, delisting and going concern news

Listings · 2026-05-22

## [TransCode Therapeutics gets Nasdaq stockholders' equity deficiency notice](https://aibio.space/news/transcode-therapeutics-gets-nasdaq-stockholders-equity-deficiency/)

Nasdaq told TransCode on May 19, 2026 that its stockholders' equity of $1,251,427 is below the $2,500,000 minimum. The company has until July 3, 2026 to submit a plan to regain compliance, and its equity had been $10,335,466 at December 31, 2025.

## Latest TransCode Therapeutics news

1. 2026-03-31 Distress [TransCode Therapeutics files NT 10-K, says 2025 annual report will be late](https://aibio.space/news/transcode-therapeutics-files-nt-10-k-says-2025-annual-report-will-late/) TransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period.
2. 2025-10-08 Mergers [TransCode agrees to buy Polynoma and sell CK Life Sciences $25 million of preferred stock](https://aibio.space/news/transcode-agrees-buy-polynoma-sell-ck-life-sciences-25-million/) After the deal, CK Life Sciences would hold about 91% of TransCode on a fully diluted basis, and existing holders about 9%. Converting the preferred stock needs stockholder approval where Nasdaq rules apply, and up to $95 million in milestones may go to CK Life Sciences.
3. 2025-05-07 Listings [TransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing](https://aibio.space/news/transcode-therapeutics-faces-nasdaq-delisting-no-grace-period-plans/) TransCode received a Nasdaq notice on May 6, 2025 that its stock would be delisted from the Nasdaq Capital Market unless it appeals. Earlier reverse splits left it with no compliance period, so it must request a hearing by May 13, 2025.
4. 2025-03-31 Distress [TransCode Therapeutics delays 2024 annual report to account for direct offering](https://aibio.space/news/transcode-therapeutics-delays-2024-annual-report-account-direct/) TransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period.
5. 2025-03-25 Financings [TransCode Therapeutics agrees to sell 10,250,000 shares and warrants at $0.98](https://aibio.space/news/transcode-therapeutics-agrees-sell-10-250-000-shares-warrants-0-98/) TransCode is selling 10,250,000 shares and warrants at $0.98 per share and warrant, through ThinkEquity LLC as exclusive placement agent, for a total offering price of $10,045,000 before fees. The prospectus shows an immediate dilution of $0.72 per share to new investors, and the auditor's report carries a going concern paragraph.

## TransCode Therapeutics at a glance

- **Ticker**: RNAZ

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $8.4 million

### Related companies

- [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) NASDAQ: CURX
- [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) OTC: TSOI
- [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) NASDAQ: DFTX
- [MIRA Pharmaceuticals](https://aibio.space/companies/mira-pharmaceuticals/) NASDAQ: MIRA
- [iBio](https://aibio.space/companies/ibio/) NASDAQ: IBIO
- [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR
- [Earth Science Tech](https://aibio.space/companies/earth-science-tech/) OTC: ETST
- [Artiva Biotherapeutics](https://aibio.space/companies/artiva-biotherapeutics/) NASDAQ: ARTV

### Also on NASDAQ

- [Prenetics Global](https://aibio.space/companies/prenetics-global/) PRE
- [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) COGT
- [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) TKNO
- [iRhythm Holdings](https://aibio.space/companies/irhythm/) IRTC
- [Korro Bio](https://aibio.space/companies/korro-bio/) KRRO
- [NuCana](https://aibio.space/companies/nucana/) NCNA

## TransCode Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$13.4 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) | [$9.7 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) |
| Net income (loss) | [-$34.7 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) | [-$16.8 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) |
| Cash from operations | [-$19.5 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) | [-$13.3 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) |
| Cash and equivalents | [$17.8 million](https://www.sec.gov/Archives/edgar/data/1829635/000182963526000003/) | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about TransCode Therapeutics

Did TransCode Therapeutics do a reverse stock split?

Our latest story on this, dated May 7, 2025: "TransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/transcode-therapeutics-faces-nasdaq-delisting-no-grace-period-plans/).

Was TransCode Therapeutics delisted?

Our latest story on this, dated May 7, 2025: "TransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/transcode-therapeutics-faces-nasdaq-delisting-no-grace-period-plans/).

Has TransCode Therapeutics issued a going-concern warning?

Our latest story on this, dated Mar 25, 2025: "TransCode Therapeutics agrees to sell 10,250,000 shares and warrants at $0.98". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/transcode-therapeutics-agrees-sell-10-250-000-shares-warrants-0-98/).

Has TransCode Therapeutics raised money recently?

Our latest story on this, dated Mar 31, 2025: "TransCode Therapeutics delays 2024 annual report to account for direct offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/transcode-therapeutics-delays-2024-annual-report-account-direct/).

Has TransCode Therapeutics received a Nasdaq deficiency notice?

Our latest story on this, dated May 22, 2026: "TransCode Therapeutics gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/transcode-therapeutics-gets-nasdaq-stockholders-equity-deficiency/).

Is TransCode Therapeutics involved in a merger or acquisition?

Our latest story on this, dated Oct 8, 2025: "TransCode agrees to buy Polynoma and sell CK Life Sciences $25 million of preferred stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/transcode-agrees-buy-polynoma-sell-ck-life-sciences-25-million/).

What is the ticker symbol of TransCode Therapeutics?

TransCode Therapeutics, Inc. trades under the ticker RNAZ on NASDAQ.

Where is TransCode Therapeutics listed?

TransCode Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of TransCode Therapeutics?

The SEC Central Index Key (CIK) for TransCode Therapeutics, Inc. is 1829635. Its filings are on SEC EDGAR.

How many shares does TransCode Therapeutics have outstanding?

16,930,739 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is TransCode Therapeutics listed under?

Our directory records TransCode Therapeutics, Inc. under United States.

What does TransCode Therapeutics do?

Our directory classifies TransCode Therapeutics, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.

What is the ISIN of TransCode Therapeutics?

The ISIN recorded for TransCode Therapeutics, Inc. is US89357L5012.

Does aibio.space cover TransCode Therapeutics?

aibio.space lists TransCode Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is TransCode Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

## Investor discussion: TransCode Therapeutics

Members talk about TransCode Therapeutics (RNAZ). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TransCode Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-10-01 Distress Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,2.04). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926112826/tm2626839d1_8k.htm)
2. 2026-07-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/tm2619681d1_8k.htm)
3. 2026-06-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926069458/tm2613174-4_def14a.htm)
4. 2026-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/tm2615385d1_8k.htm)
5. 2026-05-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926058043/tm2613174-1_pre14a.htm)
6. 2026-04-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926043810/rnaz-20251231x10k.htm)
7. 2026-04-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926040171/tm2611272d1_ex99-1.htm)
8. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926037743/tm269621d2_nt10k.htm)
9. 2026-03-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/tm267831d1_ex99-1.htm)
10. 2025-10-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925097799/tm2528282d1_ex99-1.htm)
11. 2025-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925045598/tm2514386d1_8k.htm)
12. 2025-05-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925044596/tm2514038d1_ex99-1.htm)
13. 2025-05-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925044126/tm2513881d1_ex99-1.htm)
14. 2025-04-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925036866/tm2512771d1_ex99-1.htm)
15. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925034266/tm252488-2_def14a.htm)
16. 2025-04-02 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925031238/tm252488-1_pre14a.htm)
17. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925029875/tm2510924d1_nt10k.htm)
18. 2025-03-25 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925027521/tm2510082-1_424b5.htm)
19. 2025-02-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925016947/tm257516d1_ex99-1.htm)
20. 2025-02-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465925009122/tm255410d1_ex99-1.htm)
21. 2024-11-29 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465924124097/tm2429720d2_ex99-1.htm)
22. 2024-11-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465924122379/tm2429410d1_8k.htm)
23. 2024-11-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1829635/000110465924114773/tm2427567d1_ex99-1.htm)

## Press releases

Headlines of TransCode Therapeutics's own announcements, newest first. Each opens the full release on the newswire that carried it.

1. 2026-10-28 PR Newswire [TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio](https://www.prnewswire.com/news-releases/transcode-therapeutics-retains-tungsten-advisors-to-lead-formal-strategic-process-intended-to-maximize-value-of-ttx-mc138-and-its-oncology-portfolio-302922687.html)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RNAZ on TradingView](https://www.tradingview.com/symbols/NASDAQ-RNAZ/).

## SEC filings and registration

- **SEC name**: Transcode Therapeutics, Inc.

- **CIK**: 1829635

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: RNAZ (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 6 LIBERTY SQUARE, BOSTON, MA, 02109

- **Phone**: 857-301-6857

- **Shares outstanding**: 16,930,739 as of 2026-08-10 (10-Q filed 2026-08-14)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926112826/tm2626839d1_8k.htm) filed 2026-10-01
- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/tm2626237d1_8k.htm) filed 2026-09-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926107115/tm2625146d1_8k.htm) filed 2026-09-11
- [10-Q](https://www.sec.gov/Archives/edgar/data/1829635/000182963526000003/rnaz-20260630x10q.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926089805/tm2622073d1_8k.htm) filed 2026-08-03
- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926085073/tm2620898d1_8k.htm) filed 2026-07-20
- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/tm2620727d1_8k.htm) filed 2026-07-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/tm2619681d1_8k.htm) filed 2026-07-02

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001829635), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

TransCode Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RNAZ, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: TransCode Therapeutics, Inc.

- **Ticker**: RNAZ

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biopharma / pharmaceutical profile checked

- **ISIN**: US89357L5012

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RNAZ/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/transcode-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TransCode Therapeutics (RNAZ) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/transcode-therapeutics/